TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25262266

Group type: EXPERIMENTAL
Intervention: Bleeding after PCI
Number of subjects: 96637

Group type: EXPERIMENTAL
Intervention: Transfusion after bleeding
Number of subjects: 96637
Study: 21194865

Group type: EXPERIMENTAL
Intervention: Adenosine-stress dynamic real-time myocardial perfusion CT
Number of subjects: 20

Group type: COMPARATOR
Intervention: Adenosine-stress first-pass dual-energy myocardial perfusion CT
Number of subjects: 20
Study: 20182022

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatments (specific subclasses: calcium channel blockers, angiotensin converting enzyme inhibitors, angiotensin-AT1-receptor-blockers)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Antihypertensive treatments (placebo-controlled)
Number of subjects: 7
Study: 18303097

Group type: EXPERIMENTAL
Intervention: Intermediate dose (120 mcg ipratropium bromide and 600 mcg of salbutamol using metered dose inhaler (MDI) and spacer)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: High dose (nebulized 500 mcg ipratropium bromide and 2.5 mg salbutamol)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Preferred treatment
Number of subjects: 25
Study: 16005815

Group type: EXPERIMENTAL
Intervention: Medical Symptom Validity Test (MSVT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Amsterdam Short‐Term Memory Test (ASTM)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Trail Making Test (TMT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Complex Figure Test (CFT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Digit Span
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Rey's 15‐Item‐Test (FIT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: TMT ratio TMT‐B:TMT‐A
Number of subjects: 36
Study: 12492770

Group type: EXPERIMENTAL
Intervention: Venlafaxine/Venlafaxine XR
Number of subjects: 0

Group type: COMPARATOR
Intervention: SSRIs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10071003

Group type: EXPERIMENTAL
Intervention: PENS
Number of subjects: 60

Group type: COMPARATOR
Intervention: sham-PENS
Number of subjects: 60

Group type: COMPARATOR
Intervention: TENS
Number of subjects: 60

Group type: COMPARATOR
Intervention: exercise therapies
Number of subjects: 60
Study: 7493304

Group type: EXPERIMENTAL
Intervention: 3 MU of rIFN‐alpha 2b for 6 months
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 5 MU of rIFN‐alpha 2b for 6 months
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (observed for six months)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: All patients who completed rIFN‐alpha 2b treatment
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: All patients post-therapy
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: All patients with a sustained response
Number of subjects: 39
Study: 2170963

Group type: EXPERIMENTAL
Intervention: Combination low sodium, low fat, high fibre diet
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Low sodium diet
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Low fat diet
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: High fibre diet
Number of subjects: 193
Study: 1091391

Group type: EXPERIMENTAL
Intervention: Colestipol hydrochloride (15 gm/day)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Colestipol hydrochloride and Placebo
Number of subjects: 92
Study: 31969134

Group type: EXPERIMENTAL
Intervention: Healthy High School (HHS) intervention programme
Number of subjects: 5976
Study: 31006207

Group type: EXPERIMENTAL
Intervention: Simultaneous vaccination of hepatitis E and hepatitis B (292 subjects)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Hepatitis B vaccination (159 subjects)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Hepatitis E vaccination (150 subjects)
Number of subjects: 600
Study: 28705312

Group type: EXPERIMENTAL
Intervention: Community-based lifestyle programs (weight reduction, increasing physical activity, smoking cessation)
Number of subjects: 824

Group type: EXPERIMENTAL
Intervention: Partner participation in the intervention group
Number of subjects: 824
Study: 25581612

Group type: EXPERIMENTAL
Intervention: Clinical remission (ACR/EULAR Boolean remission)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Clinical Disease Activity Index (CDAI) remission
Number of subjects: 118

Group type: COMPARATOR
Intervention: Triple therapy or tumor necrosis factor plus methotrexate treatment
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: MRI evidence of residual joint inflammation
Number of subjects: 118
Study: 23506999

Group type: EXPERIMENTAL
Intervention: varenicline
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: nicotine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: varenicline and nicotine (combined)
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 21812988

Group type: EXPERIMENTAL
Intervention: Integrated health intervention care programs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care programs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stay at the centre for prevention and reactivation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multidisciplinary teams
Number of subjects: 0
Study: 19930853

Group type: EXPERIMENTAL
Intervention: 12-week aerobic exercise programme
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-exercise (control) group
Number of subjects: 40
Study: 16829333

Group type: EXPERIMENTAL
Intervention: Personalized dietary counseling via lay health advisors (promotoras) plus tailored print materials delivered via the mail
Number of subjects: 357

Group type: COMPARATOR
Intervention: Tailored mailed print materials only
Number of subjects: 357

Group type: COMPARATOR
Intervention: Targeted mailed 'off-the-shelf' materials
Number of subjects: 357
Study: 12911358

Group type: EXPERIMENTAL
Intervention: Capnography
Number of subjects: 55

Group type: COMPARATOR
Intervention: Bronchoscopy
Number of subjects: 55
Study: 10698229

Group type: EXPERIMENTAL
Intervention: Thallium-201
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Technetium 99m sestamibi
Number of subjects: 43
Study: 10437178

Group type: EXPERIMENTAL
Intervention: Consciousness-restoring method
Number of subjects: 92

Group type: COMPARATOR
Intervention: Conventional method of acupuncture
Number of subjects: 92
Study: 8386779

Group type: EXPERIMENTAL
Intervention: Intracorporeal injections with sodium bicarbonate (0.03 mEq.)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Intracorporeal injections without sodium bicarbonate
Number of subjects: 38
Study: 3698595

Group type: EXPERIMENTAL
Intervention: Meteneprost 10 mg vaginal suppositories
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo vaginal suppositories
Number of subjects: 40
Study: 29165855

Group type: EXPERIMENTAL
Intervention: Face-to-face coaching
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telephone coaching
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 27501928

Group type: EXPERIMENTAL
Intervention: Combined hormonal contraceptives (CHC)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no CHC use)
Number of subjects: 38
Study: 24368433

Group type: EXPERIMENTAL
Intervention: Polyphenol-rich diet
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Marine LCn3s diet
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Polyphenol-rich diets
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control diet (poor in LCn3s and polyphenols)
Number of subjects: 86
Study: 22549602

Group type: EXPERIMENTAL
Intervention: Tailored activity pacing
Number of subjects: 32

Group type: COMPARATOR
Intervention: General activity pacing
Number of subjects: 32
Study: 20586028

Group type: EXPERIMENTAL
Intervention: SCCA
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: EGFR
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cyclin D1
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cyfra 21-1
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: EGFR and Cyclin D1 (combined detection)
Number of subjects: 70
Study: 17919762

Group type: EXPERIMENTAL
Intervention: Twice-daily injections of biphasic insulin aspart 30
Number of subjects: 160

Group type: COMPARATOR
Intervention: Three-times-daily injections of insulin aspart with or without NPH insulin (multiple daily injections)
Number of subjects: 160
Study: 15982125

Group type: EXPERIMENTAL
Intervention: Horizontal stimulus-response arrangements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vertical stimulus-response arrangements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experiments inducing shortening or lengthening of mean response time
Number of subjects: 0
Study: 12394797

Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 25
Study: 10516450

Group type: EXPERIMENTAL
Intervention: Bus drivers (long-term sitting)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Surgeons (control group, standing)
Number of subjects: 50
Study: 7492123

Group type: EXPERIMENTAL
Intervention: Ganciclovir
Number of subjects: 31

Group type: COMPARATOR
Intervention: CMV immunoglobulin
Number of subjects: 31
Study: 1958445

Group type: EXPERIMENTAL
Intervention: Tenoxicam (40 mg daily for 2 days, then 20 mg daily for 8 days)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 7338423

Group type: EXPERIMENTAL
Intervention: Physical training programme during the first 3 months
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Physical training programme during the second 3 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Physical training programme (both groups)
Number of subjects: 30
Study: 31868632

Group type: EXPERIMENTAL
Intervention: Four cycles of R-CHOP plus two doses of rituximab
Number of subjects: 588

Group type: COMPARATOR
Intervention: Six cycles of R-CHOP
Number of subjects: 588
Study: 28805757

Group type: EXPERIMENTAL
Intervention: Cytoflavin therapy combined with antihypertensive therapy
Number of subjects: 140

Group type: COMPARATOR
Intervention: Antihypertensive therapy alone
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 140
Study: 25970667

Group type: EXPERIMENTAL
Intervention: Daily physical activity intervention lasting 30 min over one academic year, led by preschool teachers with educational components for parents and teachers.
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: Daily physical activity intervention
Number of subjects: 709

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 709
Study: 23734250

Group type: EXPERIMENTAL
Intervention: 1-AIT (1×4 min at 90% HRmax)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 4-AIT (4×4 min at 90% HRmax)
Number of subjects: 26
Study: 21798134

Group type: EXPERIMENTAL
Intervention: Concept mapping
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional teaching methodology (Control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Feedback on concept mapping
Number of subjects: 50
Study: 19366386

Group type: EXPERIMENTAL
Intervention: Statin Choice decision aid
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard educational pamphlet
Number of subjects: 22
Study: 15792142

Group type: EXPERIMENTAL
Intervention: Pronoran (piribedil) 50 mg per day for 30 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pronoran (piribedil) 50 mg per day for 90 days
Number of subjects: 30
Study: 11845364

Group type: EXPERIMENTAL
Intervention: Acupuncture needle introduction at the Neiguan point (Pe. 6)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo point needle introduction
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Acupuncture point (Neiguan)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Both acupuncture and placebo points
Number of subjects: 51
Study: 10526806

Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (Group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nitroglycerin-induced hypotension (Group 2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (Group 3)
Number of subjects: 30
Study: 7589011

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg day‐1)
Number of subjects: 6
Study: 1771612

Group type: EXPERIMENTAL
Intervention: Concentrated ethylester compound of n‐3 fatty acids (3.15 g EPA and 1.89 g DHA daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Concentrated ethylester compound of n‐3 fatty acids
Number of subjects: 20

Group type: COMPARATOR
Intervention: Corn oil (control)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Concentrated ethylester compound of n‐3 fatty acids and Corn oil (control)
Number of subjects: 20
Study: 6751736

Group type: EXPERIMENTAL
Intervention: Pyridoxine hydrochloride (50 mg three times daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30461556

Group type: EXPERIMENTAL
Intervention: Technology-based information and coaching/support program
Number of subjects: 91

Group type: COMPARATOR
Intervention: American Cancer Society Web site (Control)
Number of subjects: 91
Study: 28577583

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 26
Study: 26544055

Group type: EXPERIMENTAL
Intervention: Alternative hydration system (2 glucose/electrolyte solutions - 'two bag system')
Number of subjects: 12

Group type: COMPARATOR
Intervention: Traditional hydration system (1 glucose/electrolyte solution)
Number of subjects: 12
Study: 23415619

Group type: EXPERIMENTAL
Intervention: Physical activity-based lifestyle intervention for 3 months
Number of subjects: 21

Group type: COMPARATOR
Intervention: Obese group (control)
Number of subjects: 21
Study: 21537127

Group type: EXPERIMENTAL
Intervention: DEB loaded with 50 mg doxorubicin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional TACE
Number of subjects: 40
Study: 19584739

Group type: EXPERIMENTAL
Intervention: Prolonged-release melatonin 2 mg (PRM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 17261960

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 232

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 232
Study: 16411342

Group type: EXPERIMENTAL
Intervention: HIV information handout
Number of subjects: 490

Group type: COMPARATOR
Intervention: Control group (no HIV information handout)
Number of subjects: 490
Study: 11772811

Group type: EXPERIMENTAL
Intervention: Esmolol bolus (1 mg/kg) and infusion (250 microg x kg(‐1) x min(‐1))
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9840471

Group type: EXPERIMENTAL
Intervention: Estrogen-progestin replacement therapy (estradiol valerate combined with medroxyprogesterone acetate)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 78
Study: 7805982

Group type: EXPERIMENTAL
Intervention: Transvaginal color Doppler ultrasound
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: CA 125 levels
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ultrasonographic morphological patterns
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combination of color Doppler and CA 125 or morphological assessments
Number of subjects: 28
Study: 2505282

Group type: EXPERIMENTAL
Intervention: Lithium (Li+)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 767094

Group type: EXPERIMENTAL
Intervention: Flap operation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Gingivectomy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Postoperative measurement (4 weeks after surgery)
Number of subjects: 20
Study: 31864574

Group type: EXPERIMENTAL
Intervention: Silicate-substituted calcium phosphate (Si-CaP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Autologous bone graft
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (Si-CaP and Autologous bone graft)
Number of subjects: 40
Study: 31533827

Group type: EXPERIMENTAL
Intervention: P-LSM (pragmatic lifestyle modification)
Number of subjects: 1725

Group type: COMPARATOR
Intervention: C-LSM (12-monthly lifestyle modification advice)
Number of subjects: 1725
Study: 28339826

Group type: COMPARATOR
Intervention: HDF (hemodiafiltration)
Number of subjects: 1616

Group type: COMPARATOR
Intervention: HD (hemodialysis)
Number of subjects: 1616
Study: 25734485

Group type: EXPERIMENTAL
Intervention: Invitation card group
Number of subjects: 462

Group type: COMPARATOR
Intervention: Standard of Care (SoC) group
Number of subjects: 462
Study: 23733379

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 540
Study: 21519744

Group type: EXPERIMENTAL
Intervention: Low glycemic load (LGL) diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: High glycemic load (HGL) diet
Number of subjects: 0
Study: 18971914

Group type: EXPERIMENTAL
Intervention: Amoxicillin 3 g per day orally for 3 months
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 16128125

Group type: EXPERIMENTAL
Intervention: Single dose of 2 g of first generation cephalosporins (Group 1, n = 200)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Control group (Group 2, n = 250)
Number of subjects: 450
Study: 12063985

Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2b plus ribavirin for 48 weeks
Number of subjects: 117

Group type: COMPARATOR
Intervention: Interferon-alpha-2b plus placebo for 24 weeks followed by 24 weeks of combined therapy
Number of subjects: 117
Study: 9814724

Group type: EXPERIMENTAL
Intervention: Cetirizine (0.25mg/kg b.i.d.)
Number of subjects: 817

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 817

Group type: COMPARATOR
Intervention: Cetirizine or Placebo
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 817
Study: 7649921

Group type: EXPERIMENTAL
Intervention: Bradykinin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Methacholine
Number of subjects: 12
Study: 2672898

Group type: EXPERIMENTAL
Intervention: 20 ml 0.5% bupivacaine with epinephrine, 5 micrograms/ml
Number of subjects: 26

Group type: COMPARATOR
Intervention: 20 ml preservative-free saline
Number of subjects: 26
Study: 786663

Group type: EXPERIMENTAL
Intervention: Prorenoate potassium 45 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30185568

Group type: EXPERIMENTAL
Intervention: Hashimoto's thyroiditis (HT) cohort
Number of subjects: 1268

Group type: EXPERIMENTAL
Intervention: Hashimoto's thyroiditis (HT) cohort aged ≥50 years
Number of subjects: 1268

Group type: EXPERIMENTAL
Intervention: Hashimoto's thyroiditis (HT) cohort women
Number of subjects: 1268

Group type: EXPERIMENTAL
Intervention: Hashimoto's thyroiditis (HT) cohort without thyroxine treatment
Number of subjects: 1268

Group type: EXPERIMENTAL
Intervention: Hashimoto's thyroiditis (HT) cohort with thyroxine treatment
Number of subjects: 1268
Study: 27639827

Group type: EXPERIMENTAL
Intervention: POs‐Ca chewing gum
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: POs‐Ca+F chewing gum
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control chewing gum
Number of subjects: 37
Study: 24518166

Group type: EXPERIMENTAL
Intervention: 1-year nutrition-based comprehensive intervention weight-loss program
Number of subjects: 326

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 326
Study: 22898328

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention group (n=27) including exercise advice by a physiotherapist six times during pregnancy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (n=27) without additional exercise advice
Number of subjects: 54
Study: 21075912

Group type: EXPERIMENTAL
Intervention: Bilateral night splints for 3 weeks
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Exercise regimen for 3 weeks
Number of subjects: 22
Study: 18544992

Group type: EXPERIMENTAL
Intervention: Taxotere plus prednisolone (30 mg/m2 weekly during 5 of 6 weeks + prednisolone 5 mg orally twice daily)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Prednisolone (5 mg orally twice daily)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Taxotere plus prednisolone
Number of subjects: 134

Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 134
Study: 15975314

Group type: EXPERIMENTAL
Intervention: ABCBS herbs orally taken in addition to conventional treatment
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional treatment with western medicine (WM) and Salvia injection
Number of subjects: 88
Study: 12172089

Group type: EXPERIMENTAL
Intervention: Adolescent reproductive health intervention (ARHI)
Number of subjects: 723

Group type: COMPARATOR
Intervention: Community survey
Number of subjects: 723
Study: 9669275

Group type: EXPERIMENTAL
Intervention: 2% dodecafluoropentane emulsion (EchoGen)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Active control (sonicated human albumin [Albunex])
Number of subjects: 254
Study: 8090164

Group type: EXPERIMENTAL
Intervention: Surfactant therapy (Curosurf, 200 mg/kg) plus nasal continuous positive airway pressure
Number of subjects: 68

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure alone
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Surfactant therapy (Curosurf, 200 mg/kg) plus nasal continuous positive airway pressure (excluding 17 infants with ratios <0.15)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure alone (excluding 17 infants with ratios <0.15)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Surfactant therapy
Number of subjects: 68
Study: 2513717

Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg single dose
Number of subjects: 262

Group type: COMPARATOR
Intervention: Amoxicillin 3 g plus Probenecid 1 g single dose
Number of subjects: 262
Study: 4421738

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Codis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distalgesic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pentazocine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciba 44,328
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (after active analgesic)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (colour effect)
Number of subjects: 0